OncoMatch/Clinical Trials/NCT06745622
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Is NCT06745622 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HSK39297 tablets for paroxysmal nocturnal hemoglobinuria.
Treatment: HSK39297 tablets — This is a multicenter, open-label study to evaluate the long-term safety, tolerability and efficacy of HSK39297. Adult patients with PNH who had previously received and completed HSK39297 study treatment will be included. Eligible subjects can maintain HSK39297 treatment until the end of the study.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: (HSK39297)
have previously received and completed HSK39297 treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify